Benzinga | Nov 2, 2021 10:23AM EDT

Berkeley Lights To Present On Cell Line Development Af Complex Molecules And Accelerating Antibody Discovery Against Difficult Targets At 13th Annual PEGS Europe

Berkeley Lights, Inc. (NASDAQ:BLI), a leader in digital cell biology, today announced its participation at the 13th Annual PEGS Europe: Protein & Antibody Engineering Summit, being held virtually and in person from November 2-4, 2021, in Barcelona, Spain. PEGS is one of the industry's most preeminent events that inspires accelerated biotherapeutic protein drug development.

Berkeley Lights scientists will lead two presentations at PEGS Europe in the Antibody Engineering and Cell Line Engineering tracks:

* "Bringing Product Quality Assessment into Early Clone Selection with Opto(tm) Cell Line Development" on November 2, 2021, from 12:25 p.m. -- 12:55 p.m. UTC+1. In this presentation, participants will learn how to successfully mitigate some of the bottlenecks inherent with CHO cell line selection, particularly for complex molecules like bispecifics, by using the Opto(tm) CLD workflow on the Beacon(r) system. The workflow accelerates early cell line development (CLD) by integrating high throughput cell sorting, cloning, culture, productivity, growth, and product quality assays into a single, five-day automated process. Berkeley Lights will also introduce new capabilities, including on-chip detection of product aggregates and contaminating byproducts, that pinpoint the best clones early on -- saving valuable development time while de-risking the path to IND.

* "Leave No Hit Behind: Accelerating Lead Molecule Discovery Against Difficult Targets," on Wednesday, November 3 from 9:30 a.m. -- 10:00 a.m. UTC +1. In this presentation, participants will learn how Berkeley Lights' Opto(tm) Plasma B Discovery (OPBD) 4.0 workflow enables recovery of 1000s of hits by screening up to 100,000 plasma cells, down-selection of lead candidates by functional screening, and sequencing and re-expression of >1000 functionally characterized antibodies in one week. By maximizing the diversity of antibodies through direct functional profiling of plasma cells, the OPBD 4.0 workflow allows users to tackle even the most challenging targets.